Mylan (NYSE:MYL) COO Harry Korman sold 31,970 shares of the company’s stock on the open market in a transaction dated Thursday, March 6th. The stock was sold at an average price of $54.54, for a total transaction of $1,743,643.80. Following the completion of the transaction, the chief operating officer now directly owns 133,373 shares in the company, valued at approximately $7,274,163. Mylan Inc. (NASDAQ:MYL) stock opened at $54.78 in last session, and closed at $54.86, while the day range of Mylan Inc. (NASDAQ:MYL) stock is $53.70 – $55.16. The stock showed a positive weekly performance of -1.28%.
Akorn Inc. (NASDAQ:AKRX) reported fourth quarter non-GAAP EPS of $0.14 Monday morning, compared to $0.13 in the previous year. Akorn, Inc. (NASDAQ:AKRX) stock opened at $22.78 in last session, and closed at $22.45 by losing -1.28%. The 52 week range of $12.85 – $28.00. Company’s market capitalization is $2.16 billion.
Momenta Pharmaceuticals (NASDAQ:MNTA) was downgraded by equities researchers at The Street from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Stock Ratings Network.com reports. The analysts wrote, “Momenta Pharmaceuticals (MNTA) has been downgraded by The Street Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. ”Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) stock increased 0.74% and finished the last session at $15.01. The EPS of the stock remained -2.12. Company’s market capitalization is $768.29 million.
On February 25, 2014, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) issued a press release announcing that it expects to report financial results for the fourth quarter and full year ending December 31, 2013 after the market closes on March 12, 2014, and will hold a conference call and webcast on that date to review the 2013 financial results and to provide a business update. Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) stock opened the session at $9.76, and closed the session at $9.18. The 52 week range of the Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) stock remained $4.45 – $10.55 and the day range was $8.90 – $9.92.
Leave a Reply